7-MX has been used to treat childhood myopia in Denmark since 2009. But until now it has not been fully evaluated in long term studies, and the researchers wanted to find out how quickly myopia progresses in children taking 7-MX (Unsplash) 
Medicine

Caffeine metabolite may slow progression of Myopia in children

If proved effective in clinical trials, 7-MX could be valuable future treatment, say researchers

MedBound Times

A metabolite of caffeine, known as 7-MX, may slow the progression of short-sightedness, also known as myopia, in children, suggests observational research published online in the British Journal of Ophthalmology.

Myopia occurs when the eye grows too long, stretching and thinning it, and often starts at the age of 6–7, progressing until the age of 16–20.

It is associated with a heightened risk of various conditions that affect vision and eye health, including macular degeneration, cataracts, glaucoma and retinal detachment. Preliminary research suggests that the caffeine metabolite 7-methylxanthine, or 7-MX for short, inhibits excessive lengthening of the eye (axial elongation).

The researchers reviewed the medical records of 711 children (356 girls and 355 boys) treated for myopia at one eye clinic in Denmark between June 2000 and January 2021.

Comprehensive eye tests, including measurement of axial length, were carried out on the children. And 624 of the children took 7-MX tablets up to 1200 mg daily (average 470 mg) while 87 didn’t, for various reasons.

Their average age was 11 (range 7-15) when they started treatment, and their eye length and degree of myopia were tracked for an average of 3½ years (range 11 months–9 years).

Dioptres (D) are the units of measurement used to assess the extent of eye function: the average degree of refractive error (short-sight) to begin with was −2.43 D, which increased by an average of 1.34 D during the monitoring period. -3.00 D is regarded as moderately severe myopia; -6 D or more is regarded as severe myopia.

But with a daily dose of 1000 mg of 7-MX, that same child’s myopia would increase by −2.65 D over the next 6 years. None of the children taking 7-MX reported any side effects during the monitoring period (Unsplash)

Average axial length was 24.4mm, to start with, increasing by an average of 0.21 mm/year.Treatment with 7-MX was associated with a slower rate of worsening myopia and axial elongation, with higher doses seemingly more effective. Based on these data, the researchers estimated that for a typical 7 year old with a refractive error of −2.53 D to start with, that child’s myopia would increase by −3.49 D over the next 6 years without treatment.

But with a daily dose of 1000 mg of 7-MX, that same child’s myopia would increase by −2.65 D over the next 6 years. None of the children taking 7-MX reported any side effects during the monitoring period.

The findings echo those of experimental studies, say the researchers. But they acknowledge that their study is observational, nor were they able to account for potentially influential factors, such as genetic factors, time spent outdoors, ethnicity, and time spent on near work. Their findings cannot, therefore, establish causality. (NS/Newswise)

Eye Found Missing After Death Sparks Controversy at Patna Hospital

Semaglutide Shows Promise in Preventing Alzheimer’s Disease in Patients with Type 2 Diabetes

Respiratory Virus Season Is Here, But There Are Effective Ways To Protect Yourself And Your Family

Study: AI Could Transform How Hospitals Produce Quality Reports

Social Norms Around Masculinity Linked to Gaps in Cardiovascular Risk Detection and Treatment